Work

Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e21178

Authors: Justin F. Gainor, Arvind Ravi, Mark M. Awad, Mark Holton, Monica Arniella, Chip Stewart, Samuel Freeman, Ignaty Leshchiner, Andrew Chow, Brian S. Henick, Vamsidhar Velcheti, Aaron Timothy Griffin, Biagio Ricciuti, Jonathan W. Riess, Pasi A. Janne, Nir Hacohen, Jedd D. Wolchok, Matthew David Hellmann, Gad Getz

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Broad Institute, Memorial Sloan Kettering Cancer Center, Yale University, Cleveland Clinic, Columbia University Irving Medical Center, UC Davis Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281722379

Cites:

Cited by:

Related to: 10